These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 7522504)
1. Clinical status of the new cytoprotective agent, amifostine. Kalaycioglu M; Bukowski R Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504 [TBL] [Abstract][Full Text] [Related]
2. Use of amifostine in bone marrow purging. Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666 [TBL] [Abstract][Full Text] [Related]
3. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Douay L; Hu C; Giarratana MC; Gorin NC Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773 [TBL] [Abstract][Full Text] [Related]
4. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263 [TBL] [Abstract][Full Text] [Related]
5. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells . Haas R; Murea S Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679 [TBL] [Abstract][Full Text] [Related]
7. The potential of amifostine: from cytoprotectant to therapeutic agent. Santini V; Giles FJ Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165 [TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Patchen ML; MacVittie TJ Semin Oncol; 1994 Oct; 21(5 Suppl 11):26-32. PubMed ID: 7526469 [TBL] [Abstract][Full Text] [Related]
9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
10. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells. Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203 [TBL] [Abstract][Full Text] [Related]
11. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260 [TBL] [Abstract][Full Text] [Related]
12. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Capizzi RL; Scheffler BJ; Schein PS Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582 [TBL] [Abstract][Full Text] [Related]
13. Protection by amifostine of cyclophosphamide-induced myelosuppression. Alberts DS Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259 [TBL] [Abstract][Full Text] [Related]
14. G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967 [TBL] [Abstract][Full Text] [Related]
15. Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animals models. Patchen ML Eur J Cancer; 1995; 31A Suppl 1():S17-21. PubMed ID: 7577095 [TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449 [TBL] [Abstract][Full Text] [Related]
17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
18. Amifostine protects bone marrow from benzene-induced hematotoxicity in mice. Yu K; Yang KY; Ren XZ; Chen Y; Liu XH Int J Toxicol; 2007; 26(4):315-23. PubMed ID: 17661222 [TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells. Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323 [TBL] [Abstract][Full Text] [Related]
20. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Kurbacher CM; Mallmann PK Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]